BDSX: Bullish Engulfing detected on 20 Aug 2026

Biodesix delivered Q2 2026 revenue of $26.9 million with 34% growth and 82% gross margin, and the stock is now forming a bullish engulfing pattern at $25.54, just below the $26.4 resistance level. With a structure score of 11.0, breakout score of 8.0, and volume ratio of 2.26 (current volume 197,639 vs. 20-day average of 87,333), the setup shows moderate quality—strong volume confirmation but slightly weaker pattern geometry. RSI at 63.9 indicates room to move higher without overbought conditions. The stock sits 3.26% below its 52-week high, having rallied 385.55% from its 52-week low.

CEO Scott Hutton highlighted 34% revenue growth, 42% growth in diagnostic testing revenue, and gross margins increasing to 82%, driven by continued adoption of blood-based lung diagnostics and expanding reimbursement coverage. Test volumes grew 38% year-over-year with notable adoption from primary care (up 133%) and pulmonology (up 31%). Net loss improved 37% year-over-year while operating expenses grew only 7%, and cash position strengthened to $30 million with operational cash burn improving 70% year-over-year. Management maintained FY 2026 guidance of $108-114 million reflecting 25% growth. The company is clearly executing on both revenue acceleration and path to profitability, providing fundamental tailwind for the technical setup.

A successful bullish engulfing breakout would confirm above the $26.4 resistance level with volume sustaining above 150,000 shares (≥1.7x the 20-day average). The measured move target is $27.19 (conservative estimate), representing a 6.5% gain from breakout point. Invalidation occurs at the $19.77 key support level—a close below this would negate the pattern and suggest broader weakness. Win probability of 55.65% indicates slightly better-than-even odds, though not overwhelming. The pattern suggests a near-term consolidation breakout rather than explosive continuation.

Full-year guidance implies a slowdown in second-half growth to 16-22% year-over-year due to tougher comparisons and tougher sales force expansion progressing slower than expected (104 reps vs. planned 120). GuruFocus detected 4 warning signs with BDSX, though specifics were not disclosed. The stock's 83% three-month rally has been substantial, and while volatility at 8.14% is moderate, the recent 20.81% one-month gain leaves less margin for error. No imminent earnings risk exists post-Q2 report (August 5), but operational execution on sales expansion and margin maintenance remain critical. High beta (0.65) suggests defensive positioning, but the stock remains unprofitable.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.